A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
48actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-12 | actual | When the study began enrolling |
| Primary completion | 2025-03-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-16 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: BMS-986278 Batched method, Dose A
- Drug: BMS-986278 Batched method, Dose B
- Drug: BMS-986278 Continuous method
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax)
measured Up to Day 24
Area Under the Concentration-time From Time Zero to Time Last Qualifiable Concentration (AUC(0-T))
measured Up to Day 24
Area Under the Concentration-time From Time Zero Extrapolated to Infinite Time (AUC(INF))
measured Up to Day 24
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed